Minerva Neurosciences | NERV - DEBITO





DEBITO Cambiamento Data
Acadia Pharmaceuticals USD 50.79M 1.39M 2026-03
Adma Biologics USD 204.41M 121.28M 2026-03
ALKERMES USD 1.58B 1.51B 2026-03
Alterity Therapeutics Limited AUD 210.39K 120.67K 2023-06
AstraZeneca USD 32.24B 1.68B 2026-06
BioCryst Pharmaceuticals USD 828.6M 510K 2024-12
Bristol-Myers Squibb USD 46.43B 711M 2026-03
Cipla INR 6.14B 1.76B 2026-03
Clal Biotechnology ILS 35.76M 28.27M 2023-12
Compugen USD 2.93M 14K 2026-03
CSL USD 11.96B 219M 2024-12
Eli Lilly USD 43.37B 867M 2026-03
GlaxoSmithKline GBP 19.06B 1.34B 2026-03
Grifols EUR 9.23B 626.05M 2024-12
Halozyme Therapeutics USD 2.14B 2.01M 2026-03
Ionis Pharmaceuticals USD 1.91B 425.5M 2026-06
J&J USD 54.99B 7.05B 2026-03
Merck USD 49.12B 222M 2026-03
Minerva Neurosciences USD 0 0 2024-09
Neurocrine Biosciences USD 406.2M 9.1M 2026-03
Novartis USD 49.01B 2.02B 2026-06
Novavax USD 233.31M 4.23M 2024-09
Pfizer USD 63.19B 536M 2026-06
Roche Holding CHF 33.03B 1.41B 2025-06
Sanofi EUR 23.58B 3.56B 2026-06
Takeda JPY 4.94T 58.13B 2026-06
Vanda Pharmaceuticals USD 4.96M 4.96M 2024-12